| Christopher Murphy, MD | |
|
211 S 3rd St, Belleville, IL 62220-1915 | |
| (618) 234-2120 | |
| (618) 222-4630 |
| Full Name | Christopher Murphy |
|---|---|
| Gender | Male |
| Speciality | Pathology |
| Experience | 30 Years |
| Location | 211 S 3rd St, Belleville, Illinois |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1487764890 | NPI | - | NPPES |
| 200886160 | Medicaid | IN | |
| 1100112 | Other | UHC MEDICARE COMPLETE | |
| H20423 | Other | MERCY HEALTH PLAN | |
| 036099524 | Medicaid | IL | |
| 220030932 | Other | RAILROAD MEDICARE | |
| 238230 | Other | IL | HARMONY HEALTH |
| 5811655 | Other | AETNA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZP0102X | Pathology - Anatomic Pathology & Clinical Pathology | 036099524 (Illinois) | Primary |
| 207ZP0213X | Pathology - Pediatric Pathology | 036099524 (Illinois) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Hshs St Elizabeth's Hospital | O fallon, IL | Hospital |
| St Josephs Hospital | Breese, IL | Hospital |
| Gateway Regional Medical Center | Granite city, IL | Hospital |
| Wabash General Hospital 1 | Mount carmel, IL | Hospital |
| Clay County Hospital | Flora, IL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Associated Pathologists Ltd | 0345212866 | 11 |
| Premier Pathology Services Llc | 3577594548 | 5 |
News Archive
Developing new drugs is a highly costly and time-consuming process. Of 20 candidates, 19 are normally rejected because they don't work or have unwanted side effects. Now a research team led by Professor Lars Baltzer at Uppsala University has produced a tiny molecular "binder" that has the potential to change this landscape radically.
ViroPharma Incorporated and Halozyme Therapeutics announced today that ViroPharma has initiated an open-label, multi-dose Phase 2 study to evaluate the safety, and pharmacokinetics and pharmacodynamics of subcutaneous administration of Cinryze in combination with Halozyme's Enhanze technology, a proprietary drug delivery platform using Halozyme's recombinant human hyaluronidase enzyme, in subjects with hereditary angioedema.
Researchers have discovered a key to the function of a specific protein that helps control the levels of other critical proteins within cells, including a protein that suppresses the spread of cancer. The new information about the mechanism of action of the protein, called gp78, may enable researchers to explore new types of therapies to prevent the spread of cancer. The study, by researchers at the National Cancer Institute (NCI), part of the National Institutes of Health, was published in the June 26, 2009, issue of Molecular Cell.
State health inspectors inspect Mississippi's only abortion clinic - the first step towards shutting it down- while a judge considers whether to let the law stand. Meanwhile, anti-abortion activists hone in on other states with single abortion providers to see if they can use similar approaches to shut them down, Politico Pro reports.
› Verified 7 days ago
| Entity Name | Associated Pathologists Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174564587 PECOS PAC ID: 0345212866 Enrollment ID: O20040806000244 |
News Archive
Developing new drugs is a highly costly and time-consuming process. Of 20 candidates, 19 are normally rejected because they don't work or have unwanted side effects. Now a research team led by Professor Lars Baltzer at Uppsala University has produced a tiny molecular "binder" that has the potential to change this landscape radically.
ViroPharma Incorporated and Halozyme Therapeutics announced today that ViroPharma has initiated an open-label, multi-dose Phase 2 study to evaluate the safety, and pharmacokinetics and pharmacodynamics of subcutaneous administration of Cinryze in combination with Halozyme's Enhanze technology, a proprietary drug delivery platform using Halozyme's recombinant human hyaluronidase enzyme, in subjects with hereditary angioedema.
Researchers have discovered a key to the function of a specific protein that helps control the levels of other critical proteins within cells, including a protein that suppresses the spread of cancer. The new information about the mechanism of action of the protein, called gp78, may enable researchers to explore new types of therapies to prevent the spread of cancer. The study, by researchers at the National Cancer Institute (NCI), part of the National Institutes of Health, was published in the June 26, 2009, issue of Molecular Cell.
State health inspectors inspect Mississippi's only abortion clinic - the first step towards shutting it down- while a judge considers whether to let the law stand. Meanwhile, anti-abortion activists hone in on other states with single abortion providers to see if they can use similar approaches to shut them down, Politico Pro reports.
› Verified 7 days ago
| Entity Name | Premier Pathology Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1306834346 PECOS PAC ID: 3577594548 Enrollment ID: O20050830000208 |
News Archive
Developing new drugs is a highly costly and time-consuming process. Of 20 candidates, 19 are normally rejected because they don't work or have unwanted side effects. Now a research team led by Professor Lars Baltzer at Uppsala University has produced a tiny molecular "binder" that has the potential to change this landscape radically.
ViroPharma Incorporated and Halozyme Therapeutics announced today that ViroPharma has initiated an open-label, multi-dose Phase 2 study to evaluate the safety, and pharmacokinetics and pharmacodynamics of subcutaneous administration of Cinryze in combination with Halozyme's Enhanze technology, a proprietary drug delivery platform using Halozyme's recombinant human hyaluronidase enzyme, in subjects with hereditary angioedema.
Researchers have discovered a key to the function of a specific protein that helps control the levels of other critical proteins within cells, including a protein that suppresses the spread of cancer. The new information about the mechanism of action of the protein, called gp78, may enable researchers to explore new types of therapies to prevent the spread of cancer. The study, by researchers at the National Cancer Institute (NCI), part of the National Institutes of Health, was published in the June 26, 2009, issue of Molecular Cell.
State health inspectors inspect Mississippi's only abortion clinic - the first step towards shutting it down- while a judge considers whether to let the law stand. Meanwhile, anti-abortion activists hone in on other states with single abortion providers to see if they can use similar approaches to shut them down, Politico Pro reports.
› Verified 7 days ago
| Entity Name | Southern Illinois Histology, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215208798 PECOS PAC ID: 7517128143 Enrollment ID: O20120409000298 |
News Archive
Developing new drugs is a highly costly and time-consuming process. Of 20 candidates, 19 are normally rejected because they don't work or have unwanted side effects. Now a research team led by Professor Lars Baltzer at Uppsala University has produced a tiny molecular "binder" that has the potential to change this landscape radically.
ViroPharma Incorporated and Halozyme Therapeutics announced today that ViroPharma has initiated an open-label, multi-dose Phase 2 study to evaluate the safety, and pharmacokinetics and pharmacodynamics of subcutaneous administration of Cinryze in combination with Halozyme's Enhanze technology, a proprietary drug delivery platform using Halozyme's recombinant human hyaluronidase enzyme, in subjects with hereditary angioedema.
Researchers have discovered a key to the function of a specific protein that helps control the levels of other critical proteins within cells, including a protein that suppresses the spread of cancer. The new information about the mechanism of action of the protein, called gp78, may enable researchers to explore new types of therapies to prevent the spread of cancer. The study, by researchers at the National Cancer Institute (NCI), part of the National Institutes of Health, was published in the June 26, 2009, issue of Molecular Cell.
State health inspectors inspect Mississippi's only abortion clinic - the first step towards shutting it down- while a judge considers whether to let the law stand. Meanwhile, anti-abortion activists hone in on other states with single abortion providers to see if they can use similar approaches to shut them down, Politico Pro reports.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Christopher Murphy, MD Po Box 144333, Orlando, FL 32814-4333 Ph: (407) 422-9831 | Christopher Murphy, MD 211 S 3rd St, Belleville, IL 62220-1915 Ph: (618) 234-2120 |
News Archive
Developing new drugs is a highly costly and time-consuming process. Of 20 candidates, 19 are normally rejected because they don't work or have unwanted side effects. Now a research team led by Professor Lars Baltzer at Uppsala University has produced a tiny molecular "binder" that has the potential to change this landscape radically.
ViroPharma Incorporated and Halozyme Therapeutics announced today that ViroPharma has initiated an open-label, multi-dose Phase 2 study to evaluate the safety, and pharmacokinetics and pharmacodynamics of subcutaneous administration of Cinryze in combination with Halozyme's Enhanze technology, a proprietary drug delivery platform using Halozyme's recombinant human hyaluronidase enzyme, in subjects with hereditary angioedema.
Researchers have discovered a key to the function of a specific protein that helps control the levels of other critical proteins within cells, including a protein that suppresses the spread of cancer. The new information about the mechanism of action of the protein, called gp78, may enable researchers to explore new types of therapies to prevent the spread of cancer. The study, by researchers at the National Cancer Institute (NCI), part of the National Institutes of Health, was published in the June 26, 2009, issue of Molecular Cell.
State health inspectors inspect Mississippi's only abortion clinic - the first step towards shutting it down- while a judge considers whether to let the law stand. Meanwhile, anti-abortion activists hone in on other states with single abortion providers to see if they can use similar approaches to shut them down, Politico Pro reports.
› Verified 7 days ago
Dr. Ram Sai Bala, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 211 S 3rd St, Dept. Of Pathology, Belleville, IL 62220 Phone: 618-234-2120 Fax: 618-222-4630 | |
Dr. Vidya Deshpande, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 45 Sheffield Drive, Belleville, IL 62243 Phone: 618-235-0777 Fax: 618-233-8335 | |
Dr. Olivia Jo Ludwig, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 211 S 3rd St, Belleville, IL 62220 Phone: 618-234-2120 Fax: 618-222-4630 | |
Dr. David Jeffrey Eisenstein, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 4500 Memorial Dr, Dept Pathology, Belleville, IL 62226 Phone: 618-233-7750 Fax: 314-747-1710 | |
Dolph D Haege, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 211 S 3rd St, Belleville, IL 62220 Phone: 618-234-2120 Fax: 618-222-4630 | |
Stephen Michael Olson, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 211 S 3rd St, Belleville, IL 62220 Phone: 618-234-2120 |